Navigation Links
Key Vioxx Research Was Written by Merck, Documents Allege
Date:4/15/2008

Reports say academics were paid to lend their names to ghost-written studies that exaggerated painkiller's safety

TUESDAY, April 15 (HealthDay News) -- Industry documents reveal that pharmaceutical giant Merck & Co. paid academics to put their names on Vioxx research published in top medical journals while company employees often ghost-wrote the studies on the controversial cox-2 painkiller.

The company apparently also exaggerated the safety of the medication in published clinical trials, and the academics frequently did not disclose industry financial support, the documents allege.

Two articles detailing these findings, the latest episode in the Byzantine tangle surrounding the former best-selling pain reliever, appear in the April 16 issue of the Journal of the American Medical Association.

The scope of the analysis was significant. The researchers combed through 250 documents that included 24 clinical trials, 72 review articles and numerous editorials to come to their conclusions. The Vioxx articles appeared in more than a dozen medical journals, including the New England Journal of Medicine and JAMA.

"These are extraordinary manuscripts, and they reveal the inner workings of the promotion of a drug that ultimately turned out to be a hazard," said Dr. Steven Nissen, chairman of cardiovascular medicine at the Cleveland Clinic.

Nissen, who first warned that Vioxx caused heart problems in 2001, was not involved in either paper but said that he agreed with an editorial in the same issue of the journal that "the only people that need to change to stop this are physicians."

Vioxx was pulled from the market in 2004, after a study showed the drug increased users' risks of heart attack and stroke. And last November, Merck agreed to pay $4.85 billion to settle 27,000 lawsuits from plaintiffs who said they or family members were injured or died after taking Vioxx.


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Page: 1 2 3 4

Related medicine news :

1. Special Masters Appointed in Program to Resolve U.S. VIOXX(R) Product Liability Lawsuits
2. In Post-Vioxx Era, Biologics are Reviving the Arthritis Treatment Market
3. Merck Pays More Than $400 Million to Settle Federal, State Medicaid Fraud Investigation Sparked by Qui Tam Whistleblower Case Detailing Marketing Schemes for Vioxx(R), Zocor(R), Several Other Drugs
4. Vioxx Settlement Announced
5. Vioxx Settlement Puts Painkillers Back in the Spotlight
6. The Lanier Law Firm Announces $4.85 Billion National Vioxx Settlement With Merck & Co. Inc.
7. Vioxx Ban Tied to Rise in Serious GI Trouble
8. Study Points to Cause of Vioxx Heart Risk
9. New study may explain Vioxx side-effects
10. Combining liver cancer treatments doubles survival rates, UVA researchers find
11. AUDIO from Medialink and Apple Products Research and Education Council: New Research -- Adults Who Eat Apples, Apple Juice Have Healthier Diets and Lower Risk for Metabolic Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Key Vioxx Research Was Written by Merck, Documents Allege
(Date:4/17/2014)... the first genetic variant specifically associated with the ... around 10-15 per cent of all breast cancer ... breast cancer sub-type, called invasive lobular carcinoma, gives ... this particular kind of breast cancer, which can ... today (Thursday) in the journal PloS Genetics ...
(Date:4/17/2014)... of California, San Diego School of Medicine report that ... a recent major loss are more likely to be ... study is published in this month,s issue of the ... compassionate behaviors are associated with better health and well-being ... ways to improve the outcomes of individuals whose deficits ...
(Date:4/17/2014)... New Rochelle, NY, April 17, 2014U.S. military personnel ... "blast plus impact" concussive traumatic brain injury (TBI) ... were evacuated for other medical reasons. Differences in ... and depression 6-12 months after injury are reported ... , a peer-reviewed journal from Mary Ann Liebert, ...
(Date:4/17/2014)... By discovering a new mechanism that allows blood ... at UC Irvine and the Salk Institute have opened ... prevent stroke-induced brain damage. , A complex and devastating ... and primary reason for disability in the U.S. The ... lets blood-borne material into the brain, causing the permanent ...
(Date:4/17/2014)... Cesar A. Arias, M.D., Ph.D., at The University of ... a new superbug that caused a bloodstream infection in ... 17 issue of The New England Journal of ... a class of highly-resistant bacteria known as methicillin-resistant ... cause of hospital and community-associated infections. The superbug has ...
Breaking Medicine News(10 mins):Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3Health News:The ilk of human kindness 2Health News:Long-term effects of battle-related 'blast plus impact' concussive TBI in US military 2Health News:Study IDs new cause of brain bleeding immediately after stroke 2Health News:New MRSA superbug emerges in Brazil 2
... Technologies Inc.,(TSX: NDQ), a developer of real-time imaging and image ... results for the first,quarter ended March 31, 2008. In this ... US dollars., Q1 2008 Highlights, - ... 22% increase in SPY consumable ...
... could bring screening test or treatment , , MONDAY, May ... for its role in schizophrenia, also plays a significant part ... study finds. , Although the current study was done in ... be used as a test to identify women at risk ...
... 2008, CareToLive will,take to the streets with coast-to-coast protests ... and Tampa.,Joining us will be the Cancer Cure Coalition, ... Foundation of America. We are asking all patient,advocates to ... 6 men get prostate cancer. 75 American men die ...
... InfuSystem Holdings, Inc.,(OTC Bulletin Board: INHI; INHIW; INHIU), ... clinical services, today announced,financial results and provided a ... Mr. Steve Watkins, chief executive officer, commented, "We ... quarter of operations as a stand-alone,public company, and ...
... The American Veterinary,Medical Association (AVMA) has reinforced its ... and other equines by approving a,new policy on the ... the AVMA Executive Board on April 12, 2008,states that ... opposes the,use of double-deck trailers to transport equines. The ...
... Atrium Medical Corporation today,announced that it ... of,selected lots of HYDRAGLIDE(TM) Brand Heparin-Coated Thoracic ... Thoracic,Catheters were manufactured with heparin found to ... The patient risk associated,with the presence of ...
Cached Medicine News:Health News:Novadaq Reports Financial Results for the First Quarter of 2008 2Health News:Novadaq Reports Financial Results for the First Quarter of 2008 3Health News:Novadaq Reports Financial Results for the First Quarter of 2008 4Health News:Novadaq Reports Financial Results for the First Quarter of 2008 5Health News:Novadaq Reports Financial Results for the First Quarter of 2008 6Health News:Novadaq Reports Financial Results for the First Quarter of 2008 7Health News:Novadaq Reports Financial Results for the First Quarter of 2008 8Health News:Novadaq Reports Financial Results for the First Quarter of 2008 9Health News:Novadaq Reports Financial Results for the First Quarter of 2008 10Health News:Novadaq Reports Financial Results for the First Quarter of 2008 11Health News:Gene May Be Key to Pregnancy Complication 2Health News:Gene May Be Key to Pregnancy Complication 3Health News:FDA Says, 'Wait' To Dying Men; Coast-To-Coast Prostate Cancer Demonstrations on May 30th in Protest of FDA Failure to Approve Safe, Effective Immunotherapy 2Health News:FDA Says, 'Wait' To Dying Men; Coast-To-Coast Prostate Cancer Demonstrations on May 30th in Protest of FDA Failure to Approve Safe, Effective Immunotherapy 3Health News:InfuSystem Holdings Provides Business Update and Comments on First Quarter 2008 Financial Results 2Health News:InfuSystem Holdings Provides Business Update and Comments on First Quarter 2008 Financial Results 3Health News:InfuSystem Holdings Provides Business Update and Comments on First Quarter 2008 Financial Results 4Health News:InfuSystem Holdings Provides Business Update and Comments on First Quarter 2008 Financial Results 5Health News:InfuSystem Holdings Provides Business Update and Comments on First Quarter 2008 Financial Results 6Health News:InfuSystem Holdings Provides Business Update and Comments on First Quarter 2008 Financial Results 7Health News:InfuSystem Holdings Provides Business Update and Comments on First Quarter 2008 Financial Results 8Health News:InfuSystem Holdings Provides Business Update and Comments on First Quarter 2008 Financial Results 9Health News:AVMA Opposes Use of Double-Deck Trailers for Transporting Horses and Other Equines 2Health News:Atrium Initiates Voluntary Recall Action Regarding HYDRAGLIDE(TM) Brand Heparin-Coated Thoracic Drainage Catheters Used for Autotransfusion During Cardiopulmonary Bypass Surgery 2
(Date:1/15/2014)... TORONTO , Jan. 15, 2014  According to ... medical technology market intelligence, the United ... occlusion (TEO) device markets will expand moderately through ... fastest-growing segments. In particular, increasing interest in drug-eluting ...
(Date:1/15/2014)... 15, 2014 Reportlinker.com announces that ... available in its catalogue: ... for Advanced Drug Delivery Systems -- ... http://www.reportlinker.com/p01941928/Global-Markets-and-Technologies-for-Advanced-Drug-Delivery-Systems----Focus-on-Routes-of-Administration.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology ...
(Date:1/14/2014)... , Jan. 14, 2014 InformEx, North ... sellers of high-value chemistry, will hold the 30 th ... Beach Convention Center from January 21-24. ... attendees from top pharmaceutical, fine chemical and specialty chemical companies ...
Breaking Medicine Technology:US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
... 1, 2011 Chimerix, Inc., a pharmaceutical company developing ... that Kenneth I. Moch, President and Chief Executive Officer, ... Health Care Conference on March 8, 2011, 1:30 pm ... Massachusetts. The Cowen and Company Health Care Conference is ...
... BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) today announced that ... present a company update at the Cowen Health Care Conference in ... Interested parties may access a live audio webcast of ... www.BMRN.com .  A replay of the call will be archived ...
Cached Medicine Technology:Chimerix to Present at Cowen and Company 31st Annual Health Care Conference 2Chimerix to Present at Cowen and Company 31st Annual Health Care Conference 3BioMarin to Present at the Cowen Health Care Conference 2
The Carl Zeiss Head-worn Loupes L and LC are the ideal solution if a low magnification suffices for your work and you want to keep your hands free to perform the task at hand....
... delivers higher magnification for advanced surgical procedures. ... even at the highest magnification. 3.5x, 4.5x ... precise color rendition is ideal for surgical ... coating produce a superior image. The compact ...
... XL Advantage delivers higher magnification for advanced ... true image, even at the highest magnification. ... clarity and precise color rendition is ideal ... an anti-reflective coating produce a superior image. ...
... Made up of doublet objective and ... 2.0x, 2.5x and 3.0x. The true benefit ... Movement whilst maintaining focal clarity is made ... field. The ultra lightweight aluminum bar and ...
Medicine Products: